BCDA Overview

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioCardia Inc revenue for the last quarter amounts to 0.00 USD, decreased

BioCardia Inc. EPS for the last quarter amounts to -0.19 USD, decreased -62.00

BioCardia Inc (BCDA) has 17 emplpoyees as of May 12 2026.

Today BCDA has the market capitalization of 12.14M USD.